Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Item

http://www.wikidata.org/entity/Q31132556

Q31132556

about

Aldosterone antagonists for preventing the progression of chronic kidney disease Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease Aldosterone antagonists for preventing the progression of chronic kidney disease An evolving story of angiotensin-II-forming pathways in rodents and humans Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations.Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.The systematic guideline review: method, rationale, and test on chronic heart failure.Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate.Aliskiren, the first direct renin inhibitor: assessing a role in pediatric hypertension and kidney diseases.Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control.Combining angiotensin receptor blockers with ACE inhibitors in elderly patients The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status Failure or success of electronic search strategies to identify adverse effects data.Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis.The therapeutic role of RAS blockade in chronic heart failure.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk Cardiac and vascular protection: the potential of ONTARGET.The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.You can do more to slow the progression of heart failure.Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.Nutrition and heart failure: impact of drug therapies and management strategies.Management of hypertension in chronic heart failure.Managing cardiovascular and renal risk: the potential of direct renin inhibition.Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.Recent changes in the landscape of combination RAS blockade.Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question.Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.Chronic heart failure: current evidence, challenges to therapy, and future directions.Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis.The pharmacokinetics and pharmacodynamics of valsartan in the post-myocardial infarction population.Role of single-pill combination therapy in optimizing blood pressure control in high-risk hypertension patients and management of treatment-related adverse events.The high-risk patient with heart failure with reduced ejection fraction: treatment options and challenges.Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.

P2860

Q24194979-0E091528-7930-4FD5-B146-558F8E033355 Q24235834-00D7FCAF-FD10-40E5-9677-AC262585F311 Q24239909-52D2A033-298F-4AF5-9DF0-F19C88EE9406 Q26830036-B5FBA451-19FC-4D46-AD93-14867245F1E1 Q27026079-33FF0761-3716-4816-9E1A-690047445FCE Q28748219-826522FC-0DFD-4413-9CE2-D499D3CEF2AC Q30452640-092F30D3-C01A-4F05-A9A0-79E73FA8B554 Q33414957-822F3B4F-980A-415F-810C-6A6859F50E18 Q33441898-23C87F39-68F3-49E9-95F6-CA9B4702C655 Q33554921-E2CA53D0-0D2A-47AC-B7DD-987060BC8F4C Q33756874-B3F382B1-B79A-44EF-845C-25BBAD748EC5 Q33783689-ED13BE0F-6E70-482C-8081-0043F51E988B Q33830694-032C0D16-D2CB-4024-85EB-D0FE451C54D8 Q34122611-195CDF0D-0E30-4C0A-840B-958344D06F22 Q34124779-56C966FE-4F8E-4478-AAD1-4727E836B7AC Q34238325-623BD8B0-D821-405F-826F-CCF656CA0462 Q34386587-DEF30829-4DF5-4303-B4E9-2C676C1B09E4 Q34765075-F624A7CE-B4FA-4D73-A65D-7E75EBD592AF Q34915602-D9DF39F7-F00C-4BDA-99FC-848D2568FCA1 Q35539305-652C9542-3A7C-4A76-A653-8AF91FD36F86 Q37151932-9DD10FE7-CB64-42F9-B54A-895F584E7D2F Q37158159-65B8FE92-01C0-4519-A151-398DAEBFAC68 Q37176470-8201E444-C46D-42D0-92E6-011423224801 Q37199205-37EDD357-352B-47C0-84E2-D407F1345E6D Q37216146-D957B6AA-CC1A-47D9-8C04-750D99BF749E Q37273294-4005A2D4-6314-4C97-A250-3AF8E6FC5CBB Q37401599-5CAE94C6-E609-4EF1-BD69-25C0B22A4C78 Q37451537-B38B45EC-AED6-41D5-A21A-FB69B5742BEB Q37510348-5A350FFF-94B3-4360-8B82-6CC11CB3FA7F Q37574913-ED8A6062-D14B-410E-BF7E-217C1D590789 Q37629835-13CFBF9E-5AE4-47F8-9EA1-1735A5ACB0FD Q37695746-06D1AF16-21DA-4F82-8D54-12940A30D1AB Q37781702-2D27E7FA-F574-4BF2-9481-ABBC90F08DAF Q37802083-C664AB5F-9817-4059-815C-276556487C67 Q37880858-83CAEF1C-5592-4911-A8B8-7592552D972E Q38010258-DBFF9440-ABD6-4776-A459-356FF4F089C4 Q38045417-44894668-D2D7-4C2E-B5CC-69755A0E8510 Q38048939-CB82460F-AA0D-4C2F-93B1-508DCC8055AA Q38121483-91B44E54-FA05-4D7D-84B1-3E8E4E594EA8 Q38248810-DE62AEB7-F308-4918-9903-2BF89B479CB9

P2860

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Item

http://www.wikidata.org/entity/Q31132556

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu